NKGen's Troculeucel Phase 1 Data Shows 100% Cognitive Stability/Improvement in Moderate Alzheimer's
summarizeSummary
NKGen Biotech announced highly positive combined Phase 1 data for its troculeucel therapy in moderate Alzheimer's disease, presented at AD/PD 2026. The data showed dose-responsive cognitive improvements and strong biomarker correlations, with 100% of patients demonstrating stable or improved cognitive function and 50% improving from moderate to mild stages. This significant clinical advancement is particularly critical for NKGen, which has recently reported a going concern warning and delisting to the OTC Expert Market, highlighting severe financial challenges. The compelling Phase 1 results provide a much-needed positive catalyst, potentially enhancing investor confidence and offering a lifeline for the company's pipeline amidst its precarious financial situation. Traders will closely monitor the progress of the ongoing Phase 2 trial and the company's ability to secure further financing to support its development.
At the time of this announcement, NKGN was trading at $0.15 on OTC in the Life Sciences sector, with a market capitalization of approximately $19.6M. The 52-week trading range was $0.00 to $0.91. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.